Evaluation of different scoring systems for repeating Transarterial Chemoembolization in Egyptian patients with Hepatocellular Carcinoma

1 KONYN P., AHMED A., KIM D. The current trends in the health burden of primary liver cancer across the globe. Clin Mol Hepatol. 2023; 29(2):358-362. Search in Google Scholar

2 SUNG H., FERLAY J., SIEGEL RL., LAVERSANNE M., SOERJOMATARAM I., JEMAL A., et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71:209-249. Search in Google Scholar

3 RASHED WM., KANDEIL MA., MAHMOUD MO., EZZAT S. Hepatocellular Carcinoma (HCC) in Egypt: A comprehensive overview. J Egypt Natl Canc Inst. 2020; 32:5. Search in Google Scholar

4 PISCAGLIA F., OGASAWARA S. Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment. Liver Cancer. 2018; 7(1):104-119. Search in Google Scholar

5 JIA K., YIN W., GAO Z., SHEN W., WANG F., XIE S., et al. Recommendation of mHAP and ABCR scoring systems for the decision-making of the first and subsequent TACE session in HCC patients. Eur J Gastroenterol Hepatol. 2023;35(4):461-470. Search in Google Scholar

6 SIEGHART W., HUCKE F., PINTER M., GRAZIADEI I., VOGEL W., MÜLLER C., et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatol. 2013; 57(6):2261-73. Search in Google Scholar

7 ADHOUTE X., PENARANDA G., NAUDE S., RAOUL J.L., PERRIER H., BAYLE O., et al. Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process. J Hepatol. 2015; 62(4):855–862 Search in Google Scholar

8 KIM BK., SHIM JH., KIM SU., PARK JY., KIM DY., AHN SH., et al. Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model. Liver Int. 2016; 36(1):92-9. Search in Google Scholar

9 FATOUROU EM., TSOCHATZIS EA. ART and science in using transarterial chemoembolization for retreating patients with hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2014;3(6):415. Search in Google Scholar

10 FACCIORUSSO A., LICINIO R., MUSCATIELLO N., DI LEO A., BARONE M. Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol. 2015 8; 7(16):2009-19. Search in Google Scholar

11 TERZI E., TERENZI L., VENERANDI L., CROCI L., RENZULLI M., MOSCONI C., et al. The ART score is not effective to select patients for transarterial chemoembolization retreatment in an Italian series. Dig Dis. 2014;32(6):711–716. Search in Google Scholar

12 HA Y., SHIM JH., KIM SO., KIM KM., LIM YS., LEE HC., et al. Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis. J Gastroenterol Hepatol. 2014; 29(4):787-93. Search in Google Scholar

13 KLOECKNER R., PITTON MB., DUEBER C., SCHMIDTMANN I., GALLE PR., KOCH S., et al. Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma. J Vasc Interv Radiol. 2017; 28(1):94-102. Search in Google Scholar

14 MÄHRINGER-KUNZ A., WEINMANN A., SCHMIDTMANN I., KOCH S., SCHOTTEN S., PINTO DOS SANTOS D., et al. Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma. BMC Cancer. 2018;18(1):489. Search in Google Scholar

15 HEIMBACH JK., KULIK LM., FINN RS., SIRLIN CB., ABECASSIS MM., ROBERTS LR., et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatol. 2018; 67(1):358-380. Search in Google Scholar

16 EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69(1):182-236. Search in Google Scholar

17 MÜLLER L, STOEHR F, MÄHRINGER-KUNZ A, HAHN F, WEINMANN A, KLOECKNER R. Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. J Hepatocell Carcinoma. 2021; 8:403-419. Search in Google Scholar

18 LENCIONI R., LLOVET JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30(1):52-60. Search in Google Scholar

19 BUREAU OF MEDICAL ADMINISTRATION, NATIONAL HEALTH COMMISSION OF THE PEOPLE'S REPUBLIC OF CHINA. Standardization for diagnosis and treatment of hepatocellular carcinoma (2022 edition). Zhonghua Gan Zang Bing Za Zhi. 2022; 30(4):367-388. Search in Google Scholar

20 CLINICAL GUIDELINES COMMITTEE OF CHINESE INTERVENTIONALISTS COLLEGE. Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma. Zhonghua Nei Ke Za Zhi. 2021; 60(7):599-614. Search in Google Scholar

21 HUCKE F., PINTER M., GRAZIADEI I., BOTA S., VOGEL W., MÜLLER C., et al. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. J Hepatol. 2014; 61(6):1287-96. Search in Google Scholar

22 BENGTSSON B., WIDMAN L., WAHLIN S., STÅL P., BJÖRKSTRÖM NK., HAGSTRÖM H. The risk of hepatocellular carcinoma in cirrhosis differs by etiology, age and sex: A Swedish nationwide population-based cohort study. United European Gastroenterol J. 2022;10(5):465-476. Search in Google Scholar

23 ABBASI AH., ABID S., HAQ T.U., AWAN S. Role of assessment for retreatment with Transarterial chemoembolization score in decision of Retreatment with trans-arterial chemo-embolization Sessions in patients with hepatocellular carcinoma. J Ayub Med Coll Abbottabad. 2017; 29(3):378-383 Search in Google Scholar

24 REIG M., FORNER A., RIMOLA J., FERRER-FÀBREGA J., BURREL M., GARCIA-CRIADO Á., et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681-693. Search in Google Scholar

25 KADALAYIL L., BENINI R., PALLAN L., O'BEIRNE J., MARELLI L., YU D., et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol. 2013; 24:2565–2570. Search in Google Scholar

26 PINATO DJ., ARIZUMI T., ALLARA E., JANG JW., SMIRNE C., KIM YW., et al. Validation of the hepatoma arterial embolization prognostic score in European and Asian populations and proposed modification. Clin Gastroenterol Hepatol. 2015; 13:1204–1208.e2. Search in Google Scholar

27 PARK Y., KIM SU., KIM BK., PARK JY., KIM DY., AHN SH., et al. Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial-embolization prognostic score. Liver Int. 2016; 36:100–107. Search in Google Scholar

28 CAPPELLI A., CUCCHETTI A., CABIBBO G., MOSCONI C., MAIDA M., ATTARDO S., et al. Refining prognosis after trans-arterial chemo-embolization for hepatocellular carcinoma. Liver Int. 2016; 36:729–736. Search in Google Scholar

29 HAN G., BERHANE S., TOYODA H., BETTINGER D., ELSHAARAWY O., CHAN AWH., et al. Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma: a response-based approach. Hepatol. 2020; 72:198–212. Search in Google Scholar

30 LEE YK., KIM SU., KIM DY., AHN SH., LEE KH., LEE DY., et al. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. BMC Cancer. 2013; 13:5. Search in Google Scholar

31 MEMON K., KULIK L., LEWANDOWSKI RJ., WANG E., RYU RK., RIAZ A., et al. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. J Hepatol. 2012; 56:1112–1120. Search in Google Scholar

32 KUDO M., ARIZUMI T., UESHIMA K. Assessment for retreatment (ART) score for repeated transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatol. 2014; 59:2424–2425. Search in Google Scholar

33 ARIZUMI T., UESHIMA K., IWANISHI M., MINAMI T., CHISHINA H., KONO M., et al. Evaluation of ART scores for repeated transarterial chemoembolization in Japanese patients with hepatocellular carcinoma. Oncol. 2015; 89:4–10. Search in Google Scholar

34 TSENG CL., LAI WJ., HUANG CJ., HUANG YH., SU CW., LEE IC., et al. The effectiveness of ART score in selecting patients for transarterial chemoembolization retreatment: a cohort study in Taiwan. Medicine (Baltim). 2015; 94: e1659. Search in Google Scholar

35 YANG L., ZHANG Z., SUN Y., PANG S., YAO Q., LIN P., et al. Integrative analysis reveals novel driver genes and molecular subclasses of hepatocellular carcinoma. Aging (Albany NY). 2020;12(23):23849-23871. Search in Google Scholar